Should Gemtuzumab Ozogamicin Be Re-added to the Therapeutic Armamentarium for Acute Myeloid Leukemia?
Episode Description
Although gemtuzumab ozogamicin has been withdrawn from the marketplace, three randomized trials prompt review of that decision.
We use cookies to run this site. Analytics cookies help us understand how you use it and are off until you say yes. You can change your mind at any time from the privacy preferences icon at the bottom right.We use cookies to run this site and to understand how it's used. You can opt out at any time from the privacy preferences icon at the bottom right. Cookie policy